Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 3, 2020
Principal Executive Office: Boca Raton, FL
Trading Symbol: TXMD (Nasdaq)
This filing serves as a Regulation FD disclosure to furnish an investor presentation (Exhibit 99.1) to the market. The document explicitly states that the information provided is not "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing to distribute an investor presentation rather than a financial statement containing audited or unaudited financial data.
Material Changes
No material changes to financial performance or operations are reported within the text of this specific Form 8-K. The filing solely announces the availability of an investor presentation dated March 3, 2020.
Guidance, Outlook, and Risks
Management Commentary: The company is furnishing an investor presentation for use in meetings with investors or analysts. The text notes that the presentation may be used "in whole or in part, and subject to modification."
Risks and Contingencies: The filing includes standard disclaimers that the information is not subject to the liabilities of Section 18 of the Securities Exchange Act. No specific operational risks or contingencies are detailed in the body of this report.
Key Facts for Investor Verification
- Verify the contents of the attached investor presentation (Exhibit 99.1) for actual financial data, guidance, and strategic updates, as this 8-K text does not contain them.
- Confirm that the presentation is subject to modification and has not been formally "filed" for liability purposes under Section 18.
- Note the filing date of March 3, 2020, to contextualize any forward-looking statements within the attached exhibit.